Skip to search formSkip to main contentSkip to account menu

Multiple Sclerosis, Relapsing-Remitting

Known as: Remitting Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis, Remitting-Relapsing 
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
Mitoxantrone has been approved by the FDA for worsening relapsing remitting and secondary progressive Multiple Sclerosis. However… 
Highly Cited
2005
Highly Cited
2005
Injection site reactions (ISRs) are a common side effect of subcutaneous interferon beta therapy, particularly during initiation… 
Highly Cited
2000
Highly Cited
2000
Objective: To characterize a group of patients with early MS using prognostic factors and to determine whether these prognostic… 
Highly Cited
1998
Highly Cited
1998
ABSTRACT Sixty-eight patients with relapsing-remitting multiple sclerosis (RRMS) were treated with 3 million or 9 million IU of… 
Highly Cited
1996
Highly Cited
1996
Interleukin (IL)-1 receptor antagonist (IL-1ra) is a naturally occurring inhibitor of IL-1 which binds to IL-1 receptors without… 
Highly Cited
1987
Highly Cited
1987
Comparaison des resultats obtenus au «Wisconsin Card Sorting Test» par deux types de patients atteints de sclerose en plaques… 
Highly Cited
1981
Highly Cited
1981
Serum from patients with peripheral neuropathies was tested for antiperipheral nerve myelin antibodies by complement fixation… 
Highly Cited
1933
Highly Cited
1933
There have been many articles on the subject of panniculitis in medical literature. Numerous cases have been reported in which…